Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1967 1
1968 1
1969 2
1970 1
1973 1
1977 2
1978 3
1979 2
1980 1
1981 1
1982 4
1983 5
1984 6
1985 8
1986 7
1987 7
1988 10
1989 4
1990 7
1991 6
1992 6
1993 4
1994 5
1995 9
1996 12
1997 10
1998 11
1999 14
2000 16
2001 16
2002 19
2003 20
2004 22
2005 8
2006 7
2007 11
2008 8
2009 7
2010 14
2011 21
2012 22
2013 13
2014 11
2015 25
2016 21
2017 23
2018 28
2019 26
2020 20
2021 35
2022 24
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

527 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Mittendorf EA, et al. Among authors: saji s. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. Lancet. 2020. PMID: 32966830 Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: saji s. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Turner N, et al. Among authors: saji s. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3. Breast Cancer Res Treat. 2022. PMID: 34860318 Free PMC article. Clinical Trial.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. Ueno T, et al. Among authors: saji s. BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1. BMC Med. 2022. PMID: 35462552 Free PMC article.
gamma-Aminobutyrylcholine.
KURIAKI K, YAKUSHIJI T, NORO T, SHIMIZU T, SAJI S. KURIAKI K, et al. Among authors: saji s. Nature. 1958 May 10;181(4619):1336-7. doi: 10.1038/1811336a0. Nature. 1958. PMID: 13541464 No abstract available.
Early breast cancer.
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Suzuki T, et al. Among authors: saji s. Int J Clin Oncol. 2006 Apr;11(2):108-19. doi: 10.1007/s10147-006-0564-7. Int J Clin Oncol. 2006. PMID: 16622745 Review.
Nicotine in E-cigarette smoke: cancer culprit?
Saji S, Patil SS, Alleyn M, Lockey R, Kolliputi N. Saji S, et al. J Cell Commun Signal. 2020 Mar;14(1):127-128. doi: 10.1007/s12079-019-00519-5. Epub 2019 Dec 18. J Cell Commun Signal. 2020. PMID: 31853716 Free PMC article.
527 results